Fighting Blindness & Funding The Fight With Opus Genetics' CEO Ben Yerxa, Ph.D.
Business Of Biotech · 46 minutes ·

Fighting Blindness & Funding The Fight With Opus Genetics' CEO Ben Yerxa, Ph.D.

Opus Genetics is an early-stage gene therapy company launched just last year and in unique fashion on the back of the patient advocacy group the Retinal Degeneration Fund. Already, its pipeline has developed into three candidates, the lead among them addressing Leber congenital amaurosis. Opus CEO Ben Yerxa, Ph.D. serves in triplicate as CEO at the RD Fund, Foundation Fighting Blindness, and Opus Genetics. His plate is full, but he's a man on a mission. On this episode of the Business of Biotech, Dr. Yerxa shares his story, that of Opus Genetics' unique approach to addressing inherited retinal diseases, and how the company is addressing current development and capacity challenges in the cell & gene manufacturing space.

Comments (0)

You Must Be Logged In To Comment

Similar podcasts

Foundation Fighting Blindness

Historical Blindness

Breaking Blindness Barriers - AIRSLA

Blindness and chronic illness with humor

InFocus: Low Vision and Blindness Technology

Life Sciences Connect

Business Funding Podcast